{"filings":[{"id":95730,"accession_number":"0001193125-26-211964","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.","Discontinued JANX008 (EGFR-TRACTr) development after Phase 1a; resources redirected.","Initiated clinical evaluation of JANX014 (PSMA-TRACTr); JANX007 combination with darolutamide enrolling.","BMS collaboration milestone triggered $35M payment upon development candidate nomination.","Appointed William Go, M.D., Ph.D. as Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":3733000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95729,"accession_number":"0001193125-26-187641","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Janux reclassifies director Eric Dobmeier from Class III to Class II to rebalance board classes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On April 28, 2026, Eric Dobmeier resigned as Class III director and immediately reappointed as Class II director.","Change effective to achieve more equal balance among the three director classes on the Board.","Dobmeier's service deemed uninterrupted for vesting, equity awards, and compensation purposes.","Dobmeier continues on the Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109008,"accession_number":"0001193125-26-076627","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.","R&D expenses $125.9M for FY2025 vs $68.4M; net loss $113.6M vs $69.0M in 2024.","Entered collaboration with Bristol Myers Squibb for tumor-activated therapeutic; $50M upfront + up to $800M milestones.","Appointed Dr. William Go as CMO; JANX007/008/011 trials continue enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109007,"accession_number":"0001193125-26-019520","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.","Janux responsible for preclinical through IND; BMS handles later development and commercialization.","Tiered royalties on global net sales: high-single to low-double digit percentages.","Collaboration validates Janux's TRACTr/TRACIr/ARM platforms for solid tumor oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125466,"accession_number":"0001193125-25-269518","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.","Cash, equivalents & short-term investments totaled $989.0M, down from $1.03B at Dec 31, 2024.","Enrollment ongoing in Phase 1 trials for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected Q4 2025.","G&A expense fell to $10.6M vs $17.7M, last year included $9.5M stock-comp modification charge."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142201,"accession_number":"0001193125-25-209259","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.","Company determined termination without 'Cause' under Change in Control and Severance Benefit Plan.","No successor or interim CSO announced; departure of named executive officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142200,"accession_number":"0000950170-25-105010","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q2 net loss $33.9M; cash $996M; Merck milestone $10M triggered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $996.0M at June 30, 2025, vs $1.03B at Dec 31, 2024.","R&D expenses $34.7M (Q2 2025) vs $14.9M (Q2 2024); net loss $33.9M vs $6.0M.","First patient dosed in lead Merck collaboration program triggered $10M milestone payment.","Enrollment ongoing for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected H2 2025.","R&D Day highlighted preclinical PSMA-TRACIr, TROP2-TRACTr, and CD19-ARM programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160206,"accession_number":"0000950170-25-086284","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Janux Therapeutics shareholders elect three Class I directors, ratify EY","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Campbell, Ron Barrett, and Winston Kung elected Class I directors with >42M votes each.","Ernst & Young ratified as auditor for FY2025: 56.15M for, 27K against.","Advisory vote on executive compensation approved: 53.2M for, 1.15M against.","Advisory vote favors 1-year frequency for future say-on-pay votes: 54.0M for 1 year.","59.2M shares outstanding, 56.2M present at meeting; broker non-votes of 1.87M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160205,"accession_number":"0000950170-25-066969","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).","Cash and equivalents $1.01B at March 31, 2025, down from $1.03B at Dec 31, 2024.","R&D expenses $25.1M (Q1 2025) vs $14.1M (Q1 2024); net loss $23.5M vs $14.8M.","Additional JANX007 and JANX008 data expected in H2 2025; R&D Day planned mid-2025.","Selected two dose regimens (0.3/2/6mg and 0.3/2/9mg) for Phase 1b expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178504,"accession_number":"0000950170-25-029165","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.","Net loss $69.0M for FY2024 ($20.2M Q4), vs $58.3M prior year; R&D spend $68.4M.","JANX007 PSMA-TRACTr Phase 1: 100% PSA50, 63% PSA90, 50% ORR (4/8), well-tolerated safety; data cutoff Nov 15, 2024.","JANX008 EGFR TRACTr Phase 1 enrollment ongoing; data update and R&D Day planned for 2025.","Zachariah McIver promoted to Chief Medical Officer; he previously served as Amgen's Executive Medical Director."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":10588000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195175,"accession_number":"0001193125-24-271578","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999","Gross proceeds expected ~$350M before expenses; funds to advance clinical pipeline and for general purposes","Underwriters granted 30-day option to purchase up to additional 833,333 shares","Offering expected to close Dec 6, 2024; joint book-runners: BofA, TD Cowen, Stifel, Cantor, William Blair"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195174,"accession_number":"0000950170-24-132302","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.","75% maintained PSA50 and 50% maintained PSA90 at ≥12 weeks.","50% ORR (4/8 RECIST-evaluable patients) with confirmed/unconfirmed partial responses.","CRS and TRAEs primarily cycle 1, grade 1-2; MTD not yet reached.","Two once-weekly step dose regimens identified for Phase 1b in pre-PLUVICTO 2L/3L patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195173,"accession_number":"0000950170-24-122279","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports Q3 net loss $28.1M; cash $658M; JANX007 update expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $658.0M at Sept 30, 2024 vs $344.0M at Dec 31, 2023.","Net loss $28.1M for Q3 2024 vs $11.6M in Q3 2023; R&D expenses $18.6M vs $11.9M.","G&A expenses $17.7M for Q3 2024 including $9.5M stock-based compensation from equity modifications.","Enrollment continues for JANX007 (PSMA-TRACTr) in mCRPC and JANX008 (EGFR-TRACTr) in solid tumors.","Update on JANX007 data and expansion cohort doses anticipated in 2024; JANX008 update in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":10588000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211443,"accession_number":"0000950170-24-092830","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.","Cash and investments $646.3M at June 30, 2024, up from $344.0M at Dec 31, 2023.","R&D expense flat at $14.9M; G&A expense $7.8M vs $6.9M in prior year.","Enrollment ongoing for JANX007 (PSMA) and JANX008 (EGFR) trials; JANX007 data update expected 2H 2024.","Appointed Eric Dobmeier and Natasha Hernday to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":10149000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211442,"accession_number":"0000950170-24-085321","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Janux Therapeutics board reshuffles: Lichter resigns, Barrett becomes Chair, Hernday and Dobmeier appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.","Ron Barrett, Ph.D. appointed as Chairperson of the Board.","Natasha Hernday (former Seagen CBO) and Eric Dobmeier (former Chinook CEO) join as Class II and III directors.","New directors received standard equity grants: options for 16,700 shares and RSUs for 5,000 shares each.","Hernday led Seagen's $43B Pfizer acquisition; Dobmeier led Chinook's $3.5B Novartis sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230086,"accession_number":"0000950170-24-079059","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Janux shareholders elect three Class III directors and ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors elected: Vickie Capps, Jay Lichter, and Jake Simson, each with >41 million votes for.","Ernst & Young ratified as independent auditor for FY2024 with 49,801,743 votes for, 1,682 against.","51,850,667 shares outstanding as of record date April 29, 2024; broker non-votes reported for director election.","All proposals passed; no other business items were voted on at the 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230085,"accession_number":"0000950170-24-054950","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.","Net loss $14.8M for Q1 2024, improved from $17.5M in Q1 2023; R&D expenses $14.1M vs $15.9M.","Enrollment ongoing in Phase 1 trials for JANX007 (PSMA-TRACTr in mCRPC) and JANX008 (EGFR-TRACTr in solid tumors).","JANX007 data update and expansion cohort doses anticipated in 2H 2024; JANX008 data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1252000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248523,"accession_number":"0000950170-24-028647","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.","Raised ~$320.2M net in March 2024 underwritten offering to fund clinical pipeline.","Phase 1 JANX007 in mCRPC: 83% PSA50 at first step dose ≥0.2mg; no CRS > Grade 2.","Phase 1 JANX008: NSCLC subject achieved RECIST PR with 100% target lesion reduction, no CRS.","Co-founder Dr. Tommy DiRaimondo promoted to CSO; JANX007 update expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248522,"accession_number":"0000950170-24-023257","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.","Gross proceeds ~$296.5M, up from initial $175M offering; underwriters have 30-day option for 956,450 shares.","Proceeds to fund clinical pipeline development and general corporate purposes; close expected March 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248521,"accession_number":"0000950170-24-022266","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Janux Therapeutics suspends ATM equity offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delivered written notice to BofA on Feb 28, 2024 suspending the ATM prospectus supplement.","No further sales of common stock under the Sales Agreement until a new prospectus supplement is filed.","Sales Agreement remains in full force and effect; suspension does not terminate it."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}